Skip to main content

Table 1 Cohort characteristics

From: The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas

Agemean 49.6 years (range 19–85)
VariableN
Sex
 Male45
 Female52
WHO grade
 I4
 II11
 III15
 IV70
Histotype
 Astrocytic91
 Oligodendroglial9
IDH1 status
 Wild-type66
 Mutant34
MGMT status
 Methylated45
 Unmethylated49
 Unknown6
Recurrent
 Yes38
 No62
TMZ treatment
 Pre67
 Post33
Hypermutated 
 Yes9
 No91
TOTAL100
  1. N = 100 tumors from 96 patients (two females each had two tumors in this cohort, and one male had three tumors). See Additional file 1: Table S1 for further information on each tumor. TMZ temozolomide